Vaxfab Enterprises Limited

As of June 30, 2026, Vaxfab Enterprises Limited carries a market capitalization of 1.53B, placing it among publicly traded companies globally. Its enterprise value stands at 1.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vaxfab Enterprises Limited has 25.26M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.53B versus a market cap of 1.53B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Vaxfab Enterprises Limited recorded 17.54M in income tax expense. The company reported a pretax loss of -74.28M and -91.83M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Vaxfab Enterprises Limited's stock has gained approximately 76.69% over the past 52 weeks. The 50-day moving average sits at 65.32, while the 200-day moving average is 54.61.

Over the twelve months ended June 30, 2026, Vaxfab Enterprises Limited generated 1.17B in revenue and converted that into -91.83M in net income, yielding earnings per share of -5.95. EBITDA reached -150.14M, while operating income came in at -151.06M.

Over the twelve months ended June 30, 2026, Vaxfab Enterprises Limited posted a gross margin of -4.64, reflecting its pricing power and cost economics. The operating margin of -12.90 and net profit margin of -7.84 provide insight into operational efficiency.

Vaxfab Enterprises Limited's most recent stock split took place on January 3, 2023 with a 727:1460 split ratio.